News & Updates

Blood-based biomarkers (BBBs) may potentially aid earlier detection of Alzheimer’s disease (AD) following a recent revision of diagnostic criteria supporting core biomarker–based diagnosis. Initial local experience with lecanemab, a disease-modifying therapy (DMT) for patients with mild cognitive impairment or mild dementia due to AD, was shared at Advances in Medicine (AIM) 2025.

In part 1 (dose ranging with and without dose escalation) of the phase II MariTide study, significant weight reduction and robust glycaemic improvement were achieved with maridebart cafraglutide (MariTide) – the first, long-acting, GIPR* antagonist and GLP-1R** agonist – in individuals with obesity or overweight and type 2 diabetes (T2D).